Last reviewed · How we verify
Regular human insulin or Insulin Aspart
Regular human insulin and insulin aspart bind to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Regular human insulin and insulin aspart bind to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient), Gestational diabetes mellitus.
At a glance
| Generic name | Regular human insulin or Insulin Aspart |
|---|---|
| Also known as | Humulin R, Novolin R, Novolog, NovoRapid |
| Sponsor | Vancouver General Hospital |
| Drug class | Insulin |
| Target | Insulin receptor (INSR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | FDA-approved |
Mechanism of action
Both are insulin formulations that mimic the body's natural insulin hormone. Regular human insulin is a short-acting formulation, while insulin aspart is a rapid-acting analog with a faster onset and shorter duration. They work by binding to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting anabolic metabolism.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (when oral agents are insufficient)
- Gestational diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia (PHASE4)
- Assessment of the Efficacy of the Artificial Pancreas Combined With a Qualitative Meal Size Estimation to Control Postprandial Glucose Levels (NA)
- Insulin for Hyperglycemia in Stroke Trial (PHASE4)
- Regular Insulin vs Rapid Insulin Delivered by V-Go (NA)
- Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes (PHASE2)
- Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery (PHASE4)
- A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001) (PHASE1)
- Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: